help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MIYAMOTO, S.
Right arrow Articles by MIYATAKE, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MIYAMOTO, S.
Right arrow Articles by MIYATAKE, K.

Am. J. Respir. Crit. Care Med., Volume 161, Number 2, February 2000, 487-492

Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension
Comparison with Cardiopulmonary Exercise Testing

SHOICHI MIYAMOTO, NORITOSHI NAGAYA, TORU SATOH, SHINGO KYOTANI, FUMIO SAKAMAKI, MASATOSHI FUJITA, NORIFUMI NAKANISHI, and KUNIO MIYATAKE

Division of Cardiology, Department of Medicine, National Cardiovascular Center, Osaka; and College of Medical Technology, Kyoto University, Kyoto, Japan

The six-minute walk test is a submaximal exercise test that can be performed even by a patient with heart failure not tolerating maximal exercise testing. To elucidate the clinical significance and prognostic value of the six-minute walk test in patients with primary pulmonary hypertension (PPH), we sought (1) to assess the relation between distance walked during the six-minute walk test and exercise capacity determined by maximal cardiopulmonary exercise testing, and (2) to investigate the prognostic value of the six-minute walk test in comparison with other noninvasive parameters. The six-minute walk test was performed in 43 patients with PPH, together with echocardiography, right heart catheterization, and measurement of plasma epinephrine and norepinephrine. Symptom-limited cardiopulmonary exercise testing was performed in a subsample of patients (n = 27). Distance walked in 6 min was significantly shorter in patients with PPH than in age- and sex-matched healthy subjects (297 ± 188 versus 655 ± 91 m, p < 0.001). The distance significantly decreased in proportion to the severity of New York Heart Association functional class. The distance walked correlated modestly with baseline cardiac output (r = 0.48, p < 0.05) and total pulmonary resistance (r = -0.49, p < 0.05), but not significantly with mean pulmonary arterial pressure. In contrast, the distance walked correlated strongly with peak V O2 (r = 0.70, p < 0.001), oxygen pulse (r = 0.57, p < 0.01), and V E-VCO2 slope (r = -0.66, p < 0.001) determined by cardiopulmonary exercise testing. During a mean follow-up period of 21 ± 16 mo, 12 patients died of cardiopulmonary causes. Among noninvasive parameters including clinical, echocardiographic, and neurohumoral parameters, only the distance walked in 6 min was independently related to mortality in PPH by multivariate analysis. Patients walking < 332 m had a significantly lower survival rate than those walking farther, assessed by Kaplan-Meier survival curves (log-rank test, p < 0.01). These results suggest that the six-minute walk test, a submaximal exercise test, reflects exercise capacity determined by maximal cardiopulmonary exercise testing in patients with PPH, and it is the distance walked in 6 min that has a strong, independent association with mortality. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
C. G. Cote, V. M. Pinto-Plata, J. M. Marin, H. Nekach, L. J. Dordelly, and B. R. Celli
The modified BODE index: validation with mortality in COPD
Eur. Respir. J., November 1, 2008; 32(5): 1269 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. Casanova, C. Cote, J. M. Marin, V. Pinto-Plata, J. P. de Torres, A. Aguirre-Jaime, C. Vassaux, and B. R. Celli
Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD
Chest, October 1, 2008; 134(4): 746 - 752.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
O. Kowal-Bielecka, M. Delcroix, A. Vonk-Noordegraaf, M. M. Hoeper, and R. Naeije
Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis
Rheumatology, October 1, 2008; 47(suppl_5): v39 - v41.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. M. Bourbonnais and L. Samavati
Clinical predictors of pulmonary hypertension in sarcoidosis
Eur. Respir. J., August 1, 2008; 32(2): 296 - 302.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
C. E. Ventetuolo, R. L. Benza, A. J. Peacock, R. T. Zamanian, D. B. Badesch, and S. M. Kawut
Surrogate and Combined End Points in Pulmonary Arterial Hypertension
Proceedings of the ATS, July 15, 2008; 5(5): 617 - 622.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Galie, H. Olschewski, R. J. Oudiz, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al.
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Circulation, June 10, 2008; 117(23): 3010 - 3019.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. Amabile, C. Heiss, W. M. Real, P. Minasi, D. McGlothlin, E. J. Rame, W. Grossman, T. De Marco, and Y. Yeghiazarians
Circulating Endothelial Microparticle Levels Predict Hemodynamic Severity of Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1268 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
A E Lammers, A A Hislop, Y Flynn, and S G Haworth
The 6-minute walk test: normal values for children of 4-11 years of age
Arch. Dis. Child., June 1, 2008; 93(6): 464 - 468.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Lankeit, C. Dellas, A. Panzenbock, N. Skoro-Sajer, D. Bonderman, M. Olschewski, K. Schafer, M. Puls, S. Konstantinides, and I. M. Lang
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension
Eur. Respir. J., May 1, 2008; 31(5): 1024 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Heart, March 1, 2008; 94(Suppl_1): i1 - i41.
[Full Text] [PDF]

Home page
 ThoraxHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. E. King Jr., J. Behr, K. K. Brown, R. M. du Bois, L. Lancaster, J. A. de Andrade, G. Stahler, I. Leconte, S. Roux, and G. Raghu
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 75 - 81.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. G. Cote, V. Pinto-Plata, K. Kasprzyk, L. J. Dordelly, and B. R. Celli
The 6-Min Walk Distance, Peak Oxygen Uptake, and Mortality in COPD
Chest, December 1, 2007; 132(6): 1778 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
R. Naeije and S. Huez
Right ventricular function in pulmonary hypertension: physiological concepts
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H5 - H9.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J.-L. Vachiery and A. Pavelescu
Exercise echocardiography in pulmonary hypertension
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H48 - H53.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
B. G. Stevinson, J. Hernandez-Nino, G. Rose, and J. A. Kline
Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients
Eur. Heart J., October 2, 2007; 28(20): 2517 - 2524.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. L. Helman Jr, A. W. Brown, J. L. Jackson, and A. F. Shorr
Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials
Chest, September 1, 2007; 132(3): 764 - 772.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
J. D. Edelman
Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 110 - 118.
[Abstract] [PDF]

Home page
 LupusHome page
M.Y. Mok, P.L. Tsang, Y.M. Lam, Y. Lo, W.S. Wong, and C.S. Lau
Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension
Lupus, April 1, 2007; 16(4): 279 - 285.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
C. Casanova, C. G. Cote, J. M. Marin, J. P. de Torres, A. Aguirre-Jaime, R. Mendez, L. Dordelly, and B. R. Celli
The 6-min walking distance: long-term follow up in patients with COPD
Eur. Respir. J., March 1, 2007; 29(3): 535 - 540.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G.-P. Diller and M. A. Gatzoulis
Pulmonary Vascular Disease in Adults With Congenital Heart Disease
Circulation, February 27, 2007; 115(8): 1039 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
H. J. Reesink, M. N. van der Plas, N. E. Verhey, R. P. van Steenwijk, J. J. Kloek, and P. Bresser
Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension
J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 510 - 516.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al.
Recommendations on the use of exercise testing in clinical practice
Eur. Respir. J., January 1, 2007; 29(1): 185 - 209.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. O. Villalba, P. D. Sampaio-Barros, M. C. Pereira, E. M. F. P. Cerqueira, C. A. Leme Jr, J. F. Marques-Neto, and I. A. Paschoal
Six-Minute Walk Test for the Evaluation of Pulmonary Disease Severity in Scleroderma Patients
Chest, January 1, 2007; 131(1): 217 - 222.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A.-I. Raffaele, C. Andrea, P. Claudio, T. Luigi, A. Domenico, S. Aldo, I. Orsola, and R. Franco
Drawing Impairment Predicts Mortality in Severe COPD
Chest, December 1, 2006; 130(6): 1687 - 1694.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. K. Steiner, I. R. Preston, J. R. Klinger, G. J. Criner, A. B. Waxman, H. W. Farber, and N. S. Hill
Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
Chest, November 1, 2006; 130(5): 1471 - 1480.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. Souza, C. Jardim, C. Carvalho, G. Rubenfeld, A. Fijalkowska, A. Torbicki, and M. Kurzyna
The Role of NT-proBNP as a Prognostic Marker in Pulmonary Hypertension.
Chest, November 1, 2006; 130(5): 1627 - 1628.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. N. Channick, H. Olschewski, W. Seeger, T. Staub, R. Voswinckel, and L. J. Rubin
Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1433 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Matsuda, H. Ogino, K. Minatoya, H. Sasaki, N. Nakanishi, S. Kyotani, J. Kobayashi, T. Yagihara, and S. Kitamura
Long-term recovery of exercise ability after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
Ann. Thorac. Surg., October 1, 2006; 82(4): 1338 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
V. V. McLaughlin and M. D. McGoon
Pulmonary Arterial Hypertension
Circulation, September 26, 2006; 114(13): 1417 - 1431.
[Full Text] [PDF]

Home page
 CirculationHome page
N. Galie, M. Beghetti, M. A. Gatzoulis, J. Granton, R. M.F. Berger, A. Lauer, E. Chiossi, M. Landzberg, and for the Bosentan Randomized Trial of Endothelin An
Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study
Circulation, July 4, 2006; 114(1): 48 - 54.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. H. Williams, C. E. Handler, R. Akram, C. J. Smith, C. Das, J. Smee, D. Nair, C. P. Denton, C. M. Black, and J. G. Coghlan
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension
Eur. Heart J., June 2, 2006; 27(12): 1485 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Humbert, O. Sitbon, A. Chaouat, M. Bertocchi, G. Habib, V. Gressin, A. Yaici, E. Weitzenblum, J.-F. Cordier, F. Chabot, et al.
Pulmonary Arterial Hypertension in France: Results from a National Registry
Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 1023 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
O. Tschopp, C. Schmid, R. Speich, B. Seifert, E. W. Russi, and A. Boehler
Pretransplantation bone disease in patients with primary pulmonary hypertension.
Chest, April 1, 2006; 129(4): 1002 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. J. Lettieri, S. D. Nathan, S. D. Barnett, S. Ahmad, and A. F. Shorr
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Chest, March 1, 2006; 129(3): 746 - 752.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jais, and G. Simonneau
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
Eur. Heart J., March 1, 2006; 27(5): 589 - 595.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Provencher, D. Chemla, P. Herve, O. Sitbon, M. Humbert, and G. Simonneau
Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
Eur. Respir. J., January 1, 2006; 27(1): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
N. Galie, H. A. Ghofrani, A. Torbicki, R. J. Barst, L. J. Rubin, D. Badesch, T. Fleming, T. Parpia, G. Burgess, A. Branzi, et al.
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
N. Engl. J. Med., November 17, 2005; 353(20): 2148 - 2157.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, C. Neurohr, M. Vogeser, and J. Behr
Characterization of Brain Natriuretic Peptide in Long-term Follow-up of Pulmonary Arterial Hypertension
Chest, October 1, 2005; 128(4): 2368 - 2374.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. G. Esposito, S. G. Thomas, L. Kingdon, and S. Ezzat
Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting
Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E494 - E503.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H.-J. Seyfarth, H. Pankau, S. Hammerschmidt, J. Schauer, H. Wirtz, and J. Winkler
Bosentan Improves Exercise Tolerance and Tei Index in Patients With Pulmonary Hypertension and Prostanoid Therapy
Chest, August 1, 2005; 128(2): 709 - 713.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. C. White, N. Terrin, K. B. Miller, and H. F. Ryan
Impaired Respiratory and Skeletal Muscle Strength in Patients Prior to Hematopoietic Stem-Cell Transplantation
Chest, July 1, 2005; 128(1): 145 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. R. Wilkins, G. A. Paul, J. W. Strange, N. Tunariu, W. Gin-Sing, W. A. Banya, M. A. Westwood, A. Stefanidis, L. L. Ng, D. J. Pennell, et al.
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1292 - 1297.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Ramakrishna, J. Sprung, B. S. Ravi, K. Chandrasekaran, and M. D. McGoon
Impact of Pulmonary Hypertension on the Outcomes of Noncardiac Surgery: Predictors of Perioperative Morbidity and Mortality
J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1691 - 1699.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. Bossone, B. D. Bodini, A. Mazza, and L. Allegra
Pulmonary Arterial Hypertension: The Key Role of Echocardiography
Chest, May 1, 2005; 127(5): 1836 - 1843.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Humbert
Improving survival in pulmonary arterial hypertension
Eur. Respir. J., February 1, 2005; 25(2): 218 - 220.
[Full Text] [PDF]

Home page
 ChestHome page
M. Y. C. Pang, J. J. Eng, and A. S. Dawson
Relationship Between Ambulatory Capacity and Cardiorespiratory Fitness in Chronic Stroke: Influence of Stroke-Specific Impairments
Chest, February 1, 2005; 127(2): 495 - 501.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Naeije
Breathing more with weaker respiratory muscles in pulmonary arterial hypertension
Eur. Respir. J., January 1, 2005; 25(1): 6 - 8.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
O. Sitbon, V. Gressin, R. Speich, P. S. Macdonald, M. Opravil, D. A. Cooper, T. Fourme, M. Humbert, J.-F. Delfraissy, and G. Simonneau
Bosentan for the Treatment of Human Immunodeficiency Virus-associated Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1212 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Humbert, O. Sitbon, and G. Simonneau
Treatment of Pulmonary Arterial Hypertension
N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436.
[Full Text] [PDF]

Home page
 ChestHome page
N. Suleman and A. E. Frost
Transition From Epoprostenol and Treprostinil to the Oral Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Hypertension
Chest, September 1, 2004; 126(3): 808 - 815.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
E Hachulla and J G Coghlan
A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism
Ann Rheum Dis, September 1, 2004; 63(9): 1009 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. H. Leuchte, C. Neurohr, R. Baumgartner, M. Holzapfel, W. Giehrl, M. Vogeser, and J. Behr
Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 360 - 365.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. J. Oudiz, R. J. Schilz, R. J. Barst, N. Galie, S. Rich, L. J. Rubin, and G. Simonneau
Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Chest, August 1, 2004; 126(2): 420 - 427.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. McGoon, D. Gutterman, V. Steen, R. Barst, D. C. McCrory, T. A. Fortin, and J. E. Loyd
Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 14S - 34S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
V. V. McLaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. McCrory, T. Fortin, and G. Ahearn
Prognosis of Pulmonary Arterial Hypertension*: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 78S - 92S.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. M. Hoeper, R. J. Oudiz, A. Peacock, V. F. Tapson, S. G. Haworth, A. E. Frost, and A. Torbicki
End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 48S - 55S.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
W. Klepetko, E. Mayer, J. Sandoval, E. P. Trulock, J.-L. Vachiery, P. Dartevelle, J. Pepke-Zaba, S. W. Jamieson, I. Lang, and P. Corris
Interventional and surgical modalities of treatment for pulmonary arterial hypertension
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 73S - 80S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Peacock, R. Naeije, N. Galie, and J.T. Reeves
End points in pulmonary arterial hypertension: the way forward
Eur. Respir. J., June 1, 2004; 23(6): 947 - 953.
[Abstract] [Full Text] [PDF]
<

 Home page
 ChestHome page
S. Huez, S. Brimioulle, R. Naeije, and J.-L. Vachiery
Feasibility of Routine Pulmonary Arterial Impedance Measurements in Pulmonary Hypertension
Chest, June 1, 2004; 125(6): 2121 - 2128.
[Abstract] [Full Text] [PDF]